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Immunosuppressive therapy is an established therapeutic option in patients suﬀering from multiple sclerosis (MS). In an
open nonrandomized study we serially assessed cardiac function in 30 consecutive patients with MS before, during, and after
mitoxantrone therapy. Mitoxantrone (12mg/m2) was administered intravenously at 3-month intervals. Before each infusion,
cardiac function was assessed by history taking, resting electrocardiogram, and echocardiography. Whereas no patient experienced
clinical signs of heart failure, left ventricular pump function decreased continuously during mitoxantrone therapy and did not
recoveraftercessation.Thepresenteddatasuggestadose-dependentandlong-lastingtoxiccardiaceﬀectoflow-dosemitoxantrone
therapy in MS.
1.Introduction
In the year 2003 immunosuppressive therapy using
mitoxantrone has been approved for treatment of patients
with worsening relapsing-remitting or secondary progressive
multiple sclerosis (MS) in Germany. Due to potential side
eﬀects on the heart and bone marrow the cumulative dose
of mitoxantrone was initially limited to 100mg/m2 and later
on extended to 140mg/m2 in selected cases.
However, systematic data on the course and incidence
of cardiac toxicity following low-dose mitoxantrone are
lacking. In the following, we report about serial cardiac
evaluation in 30 consecutive patients before, during, and
after mitoxantrone treatment in consecutive patients with
MS. In the years 2006 and 2008, parts of the study have
been published in German language in journals which are
not indexed by PubMed [1, 2].
2. Methods
From January 2003 to July 2004, thirty consecutive patients
with secondary progressive or worsening relapsing multi-
ple sclerosis were treated with mitoxantrone at 3-month
intervals. Treatment was initiated and terminated at the
discretion of the attending neurologist. It was agreed among
the participating physicians that termination of treatment
due to cardiac reasons was limited to clinical heart failure
only. Mitoxantrone infusion as well as cardiac evaluation
before, during, and after treatment was performed by a car-
diologist. All patients were treated ambulatory and received
a pneumococcal vaccination before treatment was initiated.
In the following we focus on the cardiac evaluation of
mitoxantrone infusion. Prior to each treatment, all patients
underwent a careful history taking, laboratory testing, a
restingelectrocardiogram(ECG),andatransthoraciccardiac
ultrasound. On all occasions, mitoxantrone at a dose of2 Multiple Sclerosis International
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Figure 1: (a) Time course of left ventricular ejection fraction (EF%) during mitoxantrone treatment of 19 patients. In several patients, time
on treatment was prolonged due to temporary interruptions of treatment. The time course of individual patients is denoted by the same
letter throughout Figures 1(a) and 1(b). (b) Time course of left ventricular ejection fraction (EF%) after the end of mitoxantrone treatment
in the same 19 patients is shown in Figure 1(a).
12mg/m2 diluted in 250ml saline was infused over a period
of 30 minutes.
The electrocardiogram was obtained by a digital 12-
channel system (Custo Cardio 130, Ottobrunn) in recum-
bent position. Heart rate was averaged over a period of 30
seconds.
Cardiac imaging was performed using a digital ult-
rasound system (Vivid 3, General Electrics, Solingen). Car-
diac chamber measurements (mm), calculation of fractional
shortening (FS%), and respective ejection fraction (EF%)
were done on M-mode images only; values were determined
as an average of three consecutive measurements. Global
assessment of cardiac function and valvular disease was
performed on two-dimensional views.
3. Statistics
The relation between EF, FS, LVEDD, and heart rate with
the cumulative mitoxantrone dose was analyzed using linear
regression analysis with random coeﬃcients (software SAS
9.1, proc mixed). The course of each patient was linearly
modeled and the population average (trend) estimated
respecting age and gender. P values less than 5% were
considered statistically signiﬁcant.
4. Results
30 consecutive patients (23 female, 7 male) with a mean age
of 47 ± 10 years were treated with mitoxantrone. No patient
had received mitoxantrone, a mediastinal radiation, or any
cancer treatment before the present mitoxantrone therapy.
Three patients suﬀered from noninsulin-dependent diabetes
(10%), 2 patients from essential hypertension (7%), and 4
patients from depression. No patient suﬀered from renal
insuﬃciency. Prior to mitoxantrone treatment 8 patients
had been treated with interferon (27%), 3 with azathioprine
(10%), 1 with glatiramer acetate (3%), 2 with interferon and
azathioprine (7%), 1 with glatiramer acetate and interferon
(3%), and 1 with immunoglobulins (3%).
In 4/30 patients mitoxantrone therapy had been started
during hospitalization elsewhere (9 courses) and continued
mitoxantrone treatment as all other 26 patients ambulatory.
All reported data refer to the data obtained in all 30
patients during ambulatory treatment only. Mitoxantrone
was infused 222 times with a mean cumulative dosage of 83
±37mg/m2 (minimaldose24mg/m2,maximal156mg/m2).
Treatment frequency ranged from 2 to 13 infusions per
patient and extended over a mean period of 23 ± 13 months
(minimal 3, maximal 53 months).
During therapy with mitoxantrone 3 patients (10%)
experienced an acute episode of relapsing symptoms, one
after the ﬁrst course, one after the 4th, and one after the
5th course of mitoxantrone. In two of these 3 patients,
an additional high-dose course of intravenous steroids was
administered. At the terminal mitoxantrone infusion 5/30
(17%) reported about amelioration of MS symptoms as
compared to symptoms at the start of therapy, 19/30
(63%) about no change, and 6/30 (20%) about worsening
symptoms.
Out of 30 treated patients a total of 19 patients (63%)
had one or more cardiac exams following termination of
mitoxantrone infusion. Nine out of 19 patients (47%) had
only one followup. The followup extended over a mean
period of 30 ± 14 months (minimal 6, maximal 56 months).Multiple Sclerosis International 3
Table 1: Mean values for heart rate, left ventricular enddiastolic
dimension(LVEDD),ejectionfraction(EF),andfractionalshorten-
ing (FS). Standard deviation and number of patients in parenthesis.
∗Pvalue ≤ .05.
Treatment
start
At cessation
of treatment
At the
beginning of
follow-up
At the end
Heart rate
(rpm) 77 (12, 28) 76 (16, 30) 76 (14, 19) 73 (13, 19)
LVEDD
(mm) 46 (5, 25) 44 (5, 27) 45 (5, 19) 46 (5, 19)
EF (%) 71 (9, 24) 65 (9, 27)∗ 63 (6, 19) 62 (7, 19)
FS (%) 41 (8, 24) 36 (6, 26)∗ 33 (5, 19) 33 (5, 19)
4.1. Cardiac Evaluation. At the start of mitoxantrone ther-
apy, history taking and a careful exam revealed no cardiac
disease in any patient. During and after mitoxantrone treat-
mentnopatientdevelopedcardiacfailureorwashospitalized
for any reason.
RestingECGwasnormalbefore,during,andaftermitox-
antrone treatment in all patients. Mean heart rate averaged
77 ± 11rpm before treatment and did not change signiﬁ-
cantly during and after mitoxantrone treatment (Table 1).
Whereas heart rate and left end diastolic dimension did
not change signiﬁcantly during and after therapy, fractional
shortening (FS) as well as ejection fraction (EF) decreased
continuously and statistically signiﬁcantly during mitox-
antrone treatment in the study population of 30 patients
(Table 1). During followup of 19 patients, cardiac pump
functionasdeterminedbyFSandEFdidnotrecover(Figures
1(a) and 1(b) for 19 patients during and after treatment).
In contrast, 2D echocardiography did not reveal any visible
deterioration of global left ventricular function. No patient
developed valvular problems or signs of endocarditis.
5. Discussion
Mitoxantrone therapy is an established option for the treat-
ment of multiple sclerosis [3]. Apart from therapy-related
acute leukemia, cardiac pump failure is considered as the
mostserioussideeﬀect[3,4].Accordingtopublishedreports
mitoxantrone cardiotoxicity occurs infrequently; however,
this problem has not been assessed systematically. In some
studies cardiac function and respective ejection fraction
have been evaluated by various diﬀerent methods [5]. In
other smaller studies, cardiac function has been addressed
only before and at the end of treatment leaving the results
subject to alpha and beta errors [6]. In the present study,
cardiacfunctionhasbeenexploredsystematicallyandserially
allowing for longitudinal intraindividual observations of
cardiac function. In 30 patients treated with mitoxantrone
at a mean dosage of 83 ± 37mg/m2, left ventricular pump
function decreased continuously without clinical signs of
heart failure. Following termination of treatment, cardiac
functiondidnotrecover,suggestingalong-lastingtoxiceﬀect
of mitoxantrone on the heart. Our ﬁndings are supported by
publications of Avasarala et al. [7] and Pattoneri et al. [8]b u t
contrast with studies of De Castro et al. [9] and Zingler et al.
[10]whofoundnodeclineinleftventricularfunctionduring
serial assessment using echocardiography.
Based on numerous reports of early and late onset
cardiotoxicity in individuals with low-dose mitoxantrone
and our observations of dose-dependent eﬀects on the
heart, serial determination of cardiac function in each
patient seems indicated. Although cardiac pump function
and respective ejection fraction can be determined by
various methods, transthoracic echocardiography is cost-
eﬀective and available everywhere; radionuclide studies or
magnetic resonance imaging should be reserved to selected
patients with questionable results. Whether ejection fraction
is calculated linearily using M-mode echocardiograms or
volumetrically using planimetry of monoplane or biplane
projections in patients with suspected nonischemic car-
diomyopathy is of minor importance as long as the reeval-
uation monitoring employs the same method through-
out the course of chemotherapy and its followup. Apart
from the evaluation of systolic cardiac pump function by
echocardiography, repetitive careful history taking and the
serial determination of brain natriuretic petide may guide
the followup [11]. Parameters of impaired relaxation and
respective abnormalities in diastolic ﬁlling of the heart may
precede reductions in systolic pump function and respective
ejection fraction, in patients receiving chemotherapy [12].
On the basis of the current paper, we suggest to inform
the patient about the potential insidious nature of cardiac
toxicity and to monitor cardiac function in every patient
prior and, systematically, during mitoxantrone therapy. It
seems that cardiac function does not deteriorate further
when mitoxantrone therapy has stopped. In future studies,
it should be tested by longitudinal serial analysis whether
pretreatment with dexrazoxane will limit the slow decline of
left ventricular function as has been reported by Bernitsas et
al. [13].
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